Details of the Drug

General Information of Drug (ID: DMX3O0D)

Drug Name
UFT
Synonyms Futraful; Orzel; UFUR; Tegafur + uracil; UFT + leucovorin; BMS-200604-01; Tegafur + uracil, Taiho/Bristol-Myers Squibb
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 312.25
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 1
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 6
ADMET Property
Elimination
Less than 20% of the administered dose of tegafur is excreted intact in the urine following the oral administration [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 11 hours [3]
Metabolism
The drug is metabolized via the liver [2]
Vd
The volume of distribution (Vd) of drug is 474 L []
Chemical Identifiers
Formula
C12H13FN4O5
IUPAC Name
5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione
Canonical SMILES
C1CC(OC1)N2C=C(C(=O)NC2=O)F.C1=CNC(=O)NC1=O
InChI
InChI=1S/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8)
InChIKey
DHMYGZIEILLVNR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
104747
CAS Number
74578-38-4
DrugBank ID
DB09327
TTD ID
D0Y8PT
INTEDE ID
DR1540
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2A6 (CYP2A6)
Main DME 		DEJVYAZ CP2A6_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Equilibrative nucleoside transporter 1 (SLC29A1) OTLOOZZS S29A1_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of Taiho Pharmaceutical.
2 UFT (uracil/tegafur) capsules_Product information
3 Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer. 2004 Aug 16;91(4):613-7.
4 UFT Capsules (uracil-tegafur).
5 Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Pancreas. 2006 Aug;33(2):142-7. doi: 10.1097/01.mpa.0000226882.48204.26.